MX2013004086A - Metodos para inhibir proliferacion celular en cancers accionados por egfr. - Google Patents
Metodos para inhibir proliferacion celular en cancers accionados por egfr.Info
- Publication number
- MX2013004086A MX2013004086A MX2013004086A MX2013004086A MX2013004086A MX 2013004086 A MX2013004086 A MX 2013004086A MX 2013004086 A MX2013004086 A MX 2013004086A MX 2013004086 A MX2013004086 A MX 2013004086A MX 2013004086 A MX2013004086 A MX 2013004086A
- Authority
- MX
- Mexico
- Prior art keywords
- egfr
- methods
- cell proliferation
- inhibiting cell
- driven cancers
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 108060006698 EGF receptor Proteins 0.000 title 1
- 230000004663 cell proliferation Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 3
- 239000005411 L01XE02 - Gefitinib Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 abstract 1
- 229960002584 gefitinib Drugs 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6568—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39329110P | 2010-10-14 | 2010-10-14 | |
| PCT/US2011/056457 WO2012051587A1 (en) | 2010-10-14 | 2011-10-14 | Methods for inhibiting cell proliferation in egfr-driven cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013004086A true MX2013004086A (es) | 2013-07-05 |
Family
ID=45938740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013004086A MX2013004086A (es) | 2010-10-14 | 2011-10-14 | Metodos para inhibir proliferacion celular en cancers accionados por egfr. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140024620A1 (OSRAM) |
| EP (1) | EP2627179A4 (OSRAM) |
| JP (1) | JP2013539795A (OSRAM) |
| KR (1) | KR20130139999A (OSRAM) |
| CN (2) | CN104814970A (OSRAM) |
| AU (1) | AU2011315831B2 (OSRAM) |
| BR (1) | BR112013008816A2 (OSRAM) |
| CA (1) | CA2810900A1 (OSRAM) |
| EA (1) | EA201390550A1 (OSRAM) |
| IL (1) | IL225351A0 (OSRAM) |
| MX (1) | MX2013004086A (OSRAM) |
| WO (1) | WO2012051587A1 (OSRAM) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2300013T5 (pl) | 2008-05-21 | 2025-04-28 | Takeda Pharmaceutical Company Limited | Pochodne fosforu jako inhibitor kinazy |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| EP2704572B1 (en) | 2011-05-04 | 2015-12-30 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| JP6469567B2 (ja) * | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物 |
| EP2844642B8 (en) * | 2012-05-05 | 2019-12-25 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| CN102977104A (zh) * | 2012-11-26 | 2013-03-20 | 盛世泰科生物医药技术(苏州)有限公司 | 2,4-二氯-7-氢-吡咯并（2,3）嘧啶的合成 |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| UA115388C2 (uk) * | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань |
| CN104761544B (zh) * | 2014-01-03 | 2019-03-15 | 北京轩义医药科技有限公司 | Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂 |
| WO2015158310A1 (zh) * | 2014-04-18 | 2015-10-22 | 山东轩竹医药科技有限公司 | 一种酪氨酸激酶抑制剂及其用途 |
| US10053477B2 (en) | 2014-07-04 | 2018-08-21 | Qilu Pharmaceutical Co., Ltd. | Spirocyclic aryl phosphorus oxide and aryl phosphorus sulfide |
| CN106699810A (zh) * | 2015-11-17 | 2017-05-24 | 清华大学 | 一种含氮杂环化合物及其制备方法与在抑制激酶活性中的应用 |
| WO2017088784A1 (zh) * | 2015-11-27 | 2017-06-01 | 正大天晴药业集团股份有限公司 | 氘修饰的Brigatinib衍生物、含有该化合物的药物组合物及其用途 |
| CN109071512A (zh) * | 2016-02-03 | 2018-12-21 | 重庆复创医药研究有限公司 | 作为激酶抑制剂的含磷化合物 |
| CN107098887B (zh) * | 2016-02-22 | 2019-08-09 | 复旦大学 | 嘧啶类化合物 |
| JP6911019B2 (ja) | 2016-05-17 | 2021-07-28 | 公益財団法人がん研究会 | Ｅｇｆｒ−ｔｋｉ耐性を獲得した肺癌の治療薬 |
| WO2018044767A2 (en) | 2016-08-29 | 2018-03-08 | The Regents Of The University Of Michigan | Aminopyrimidines as alk inhibitors |
| JP7025426B2 (ja) * | 2016-11-30 | 2022-02-24 | アリアド ファーマシューティカルズ， インコーポレイテッド | 造血前駆体キナーゼ１（ｈｐｋ１）阻害剤としてのアニリノピリミジンａｓ |
| WO2018165145A1 (en) * | 2017-03-08 | 2018-09-13 | Ariad Pharmaceuticals, Inc. | Pharmaceutical formulations comprising 5-chloro-n4-[2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl} pyrimidine-2,4-diamine |
| DK3656769T3 (da) | 2017-07-19 | 2023-02-13 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Aryl-phosphor-oxygen-forbindelse som egfr-kinase-inhibitor |
| KR20200072478A (ko) * | 2017-09-08 | 2020-06-22 | 더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 | Her-구동된 약물-내성암의 치료 또는 예방을 위한 화합물, 조성물 및 방법 |
| WO2019120121A1 (zh) * | 2017-12-21 | 2019-06-27 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制激酶活性的二苯氨基嘧啶类化合物 |
| CN110305161A (zh) * | 2018-03-20 | 2019-10-08 | 暨南大学 | 2-氨基嘧啶类化合物及其应用 |
| CN110467637B (zh) * | 2018-05-09 | 2022-02-18 | 北京赛特明强医药科技有限公司 | 一种含有氧化膦类取代苯胺的双氨基氯代嘧啶类化合物、制备方法及其应用 |
| CN110467638A (zh) * | 2018-05-09 | 2019-11-19 | 北京赛特明强医药科技有限公司 | 一种含有间氯苯胺类取代基的双氨基氯代嘧啶类化合物、制备方法及其应用 |
| CN110526941A (zh) * | 2018-05-24 | 2019-12-03 | 北京赛特明强医药科技有限公司 | 一种含有间氯苯胺类取代基的吡咯并嘧啶类化合物、制备方法及其应用 |
| WO2019223777A1 (zh) * | 2018-05-24 | 2019-11-28 | 北京赛特明强医药科技有限公司 | 一种含有芳胺基取代的吡咯并嘧啶类化合物、制备方法及其应用 |
| AU2020208272A1 (en) * | 2019-01-18 | 2021-08-26 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Salt of EGFR inhibitor, crystal form, and preparation method therefor |
| CN111825719A (zh) * | 2019-04-15 | 2020-10-27 | 北京赛特明强医药科技有限公司 | 一种含有芳胺基取代的吡咯并嘧啶类化合物、制备方法及其应用 |
| CN113166103B (zh) * | 2019-04-26 | 2022-12-16 | 江苏先声药业有限公司 | Egfr抑制剂及其应用 |
| WO2020253860A1 (zh) * | 2019-06-21 | 2020-12-24 | 江苏豪森药业集团有限公司 | 芳基磷氧化物类衍生物抑制剂、其制备方法和应用 |
| WO2021003417A1 (en) | 2019-07-03 | 2021-01-07 | Sumitomo Dainippon Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof |
| US20220259235A1 (en) * | 2019-07-26 | 2022-08-18 | Betta Pharmaceuticals Co., Ltd | EGFR Inhibitor, Composition, and Preparation Method Therefor |
| WO2021018003A1 (zh) * | 2019-07-26 | 2021-02-04 | 贝达药业股份有限公司 | Egfr抑制剂、组合物及其制备方法 |
| CN112538072B (zh) * | 2019-09-21 | 2024-02-06 | 齐鲁制药有限公司 | 氨基嘧啶类egfr抑制剂 |
| WO2021057882A1 (zh) * | 2019-09-26 | 2021-04-01 | 贝达药业股份有限公司 | Egfr抑制剂、组合物及其制备方法 |
| WO2021073498A1 (zh) * | 2019-10-17 | 2021-04-22 | 贝达药业股份有限公司 | Egfr抑制剂、组合物及其制备方法 |
| AU2020385527B2 (en) * | 2019-11-21 | 2023-04-13 | Tyk Medicines, Inc. | Compound used as EGFR kinase inhibitor and use thereof |
| WO2021104441A1 (zh) * | 2019-11-29 | 2021-06-03 | 江苏先声药业有限公司 | 作为egfr激酶抑制剂的多芳基化合物 |
| KR20220141838A (ko) * | 2020-02-14 | 2022-10-20 | 베타 파머수티컬 컴퍼니 리미티드 | 퀴놀릴 포스핀 옥사이드 및 이들의 조성물과 용도 |
| AU2021227907A1 (en) * | 2020-02-25 | 2022-09-29 | Dana-Farber Cancer Institute, Inc. | Potent and selective degraders of ALK |
| EP4129996A4 (en) * | 2020-03-23 | 2023-07-12 | Qilu Pharmaceutical Co., Ltd. | Novel aminopyrimidine egfr inhibitor |
| CN111777592B (zh) * | 2020-06-22 | 2021-06-18 | 温州医科大学 | 一种n4-(2,5-二甲氧基苯基)-嘧啶二胺类靶向ddr1抑制剂及其制备和应用 |
| CN116710444A (zh) * | 2020-10-30 | 2023-09-05 | 缆图药品公司 | 嘧啶化合物、组合物及其医药应用 |
| CN116685583A (zh) * | 2020-10-30 | 2023-09-01 | 缆图药品公司 | 嘧啶化合物、组合物及其医药应用 |
| WO2022094354A1 (en) * | 2020-10-30 | 2022-05-05 | Lengo Therapeutics, Inc. | Pyrimidine compounds, compositions, and medicinal applications thereof |
| WO2022094355A1 (en) * | 2020-10-30 | 2022-05-05 | Lengo Therapeutics, Inc. | Pyrimidine compounds, compositions, and medicinal applications thereof |
| WO2022127807A1 (zh) * | 2020-12-18 | 2022-06-23 | 江苏豪森药业集团有限公司 | 一种芳基磷氧化物类衍生物自由碱的晶型及其制备方法和应用 |
| AU2022206470A1 (en) * | 2021-01-07 | 2023-07-27 | Ontario Institute For Cancer Research (Oicr) | Isoindolinone aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof |
| CA3204383A1 (en) * | 2021-01-07 | 2022-07-14 | Rima AL-AWAR | Thienyl and cycloalkyl aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof |
| CN116888108B (zh) * | 2021-03-19 | 2024-04-19 | 上海齐鲁制药研究中心有限公司 | 新型egfr降解剂 |
| WO2022199589A1 (zh) * | 2021-03-23 | 2022-09-29 | 南京明德新药研发有限公司 | 嘧啶衍生物 |
| WO2022211573A1 (ko) * | 2021-04-01 | 2022-10-06 | 주식회사 테라펙스 | 단백질 키나아제 저해 활성을 갖는 피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물 |
| EP4330251A4 (en) * | 2021-04-30 | 2025-03-05 | BeiGene Switzerland GmbH | EGFR DEGRADING AGENTS AND METHODS OF USE THEREOF |
| WO2022227032A1 (en) * | 2021-04-30 | 2022-11-03 | Beigene (Beijing) Co., Ltd. | Egfr degraders and associated methods of use |
| CN115677772B (zh) * | 2021-07-30 | 2023-08-18 | 浙江大学智能创新药物研究院 | 一种用于egfr激酶抑制剂的化合物、组合物及其应用 |
| WO2024005516A1 (ko) * | 2022-06-28 | 2024-01-04 | 보로노이 주식회사 | 헤테로아릴 유도체 화합물 및 이의 용도 |
| CN115260234A (zh) * | 2022-07-01 | 2022-11-01 | 江苏医药职业学院 | 一种2-氨基-4-氨基芳基磷氧基嘧啶化合物及其制备方法与应用 |
| CN116284001B (zh) * | 2023-01-30 | 2025-06-06 | 中国药科大学 | Dclk1抑制剂、制备方法、药物组合物和应用 |
| CN117187271B (zh) * | 2023-03-07 | 2024-08-27 | 艾博生物科技(上海)有限公司 | 编码激活性EGFR突变肽的免疫调节治疗mRNA组合物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE430742T1 (de) * | 2000-12-21 | 2009-05-15 | Smithkline Beecham Corp | Pyrimidinamine als angiogenesemodulatoren |
| WO2007056151A2 (en) * | 2005-11-03 | 2007-05-18 | Irm Llc | Protein kinase inhbitors |
| JO2660B1 (en) * | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| US8314234B2 (en) * | 2006-09-25 | 2012-11-20 | Janssen Pharmaceutica N.V. | Bicyclic pyrimidine kinase inhibitors |
| TWI389893B (zh) * | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二（芳胺基）芳基化合物 |
| US7989465B2 (en) * | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
| WO2009109605A1 (en) * | 2008-03-05 | 2009-09-11 | Novartis Ag | Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members |
| JP5298187B2 (ja) * | 2008-04-07 | 2013-09-25 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| PL2300013T5 (pl) * | 2008-05-21 | 2025-04-28 | Takeda Pharmaceutical Company Limited | Pochodne fosforu jako inhibitor kinazy |
| TWI458721B (zh) * | 2008-06-27 | 2014-11-01 | Celgene Avilomics Res Inc | 雜芳基化合物及其用途 |
| LT2585470T (lt) * | 2010-06-23 | 2017-04-10 | Hanmi Science Co., Ltd. | Nauji kondensuoti pirimidino dariniai tirozino kinazės aktyvumo slopinimui |
| EP2635285B1 (en) * | 2010-11-01 | 2017-05-03 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| EP2637502B1 (en) * | 2010-11-10 | 2018-01-10 | Celgene CAR LLC | Mutant-selective egfr inhibitors and uses thereof |
-
2011
- 2011-10-14 BR BR112013008816A patent/BR112013008816A2/pt not_active IP Right Cessation
- 2011-10-14 JP JP2013534053A patent/JP2013539795A/ja active Pending
- 2011-10-14 MX MX2013004086A patent/MX2013004086A/es not_active Application Discontinuation
- 2011-10-14 AU AU2011315831A patent/AU2011315831B2/en active Active
- 2011-10-14 CN CN201510102987.2A patent/CN104814970A/zh active Pending
- 2011-10-14 EP EP11833524.9A patent/EP2627179A4/en not_active Withdrawn
- 2011-10-14 WO PCT/US2011/056457 patent/WO2012051587A1/en not_active Ceased
- 2011-10-14 EA EA201390550A patent/EA201390550A1/ru unknown
- 2011-10-14 US US13/878,744 patent/US20140024620A1/en not_active Abandoned
- 2011-10-14 CN CN201180049813.4A patent/CN103153064B/zh active Active
- 2011-10-14 KR KR1020137012320A patent/KR20130139999A/ko not_active Withdrawn
- 2011-10-14 CA CA2810900A patent/CA2810900A1/en not_active Abandoned
-
2013
- 2013-03-20 IL IL225351A patent/IL225351A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN104814970A (zh) | 2015-08-05 |
| EA201390550A1 (ru) | 2013-08-30 |
| AU2011315831B2 (en) | 2015-01-22 |
| EP2627179A1 (en) | 2013-08-21 |
| KR20130139999A (ko) | 2013-12-23 |
| US20140024620A1 (en) | 2014-01-23 |
| IL225351A0 (en) | 2013-06-27 |
| CA2810900A1 (en) | 2012-04-19 |
| CN103153064B (zh) | 2015-04-22 |
| AU2011315831A1 (en) | 2013-03-28 |
| EP2627179A4 (en) | 2014-04-02 |
| JP2013539795A (ja) | 2013-10-28 |
| WO2012051587A1 (en) | 2012-04-19 |
| CN103153064A (zh) | 2013-06-12 |
| BR112013008816A2 (pt) | 2016-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013004086A (es) | Metodos para inhibir proliferacion celular en cancers accionados por egfr. | |
| EA024630B9 (ru) | Производные пиразола как ингибиторы ионных каналов, активируемых высвобождением кальция (crac) | |
| MX360404B (es) | Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr. | |
| MX2015006152A (es) | Compuestos de aminopirimidina como inhibidores de mutantes de egfr que contienen t7 9 0m. | |
| MX2012000709A (es) | Inhibidores de pirrolopiridina de cinasas. | |
| UA115983C2 (uk) | Інгібітори днк-пк | |
| WO2012016133A3 (en) | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers | |
| MY193562A (en) | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors | |
| NZ630925A (en) | Pyrazolopyrimidine compounds as kinase inhibitors | |
| EA201391114A1 (ru) | Способы использования alk-ингибиторов | |
| MX2012000711A (es) | Inhibidores de pirrolopirazina de cinasas. | |
| NZ604480A (en) | Morpholino pyrimidines and their use in therapy | |
| MY177344A (en) | Compounds and their methods of use | |
| MX2013009873A (es) | Inhibidores triciclicos de cinasas. | |
| MX344335B (es) | Derivados de benzonitrilo como inhibidores de cinasa. | |
| MX2012009030A (es) | Identificacion de mutacion lkb1 como biomarcador predictivo para sensibilidad a inhibidores de tor cinasa. | |
| IN2012DN02081A (OSRAM) | ||
| IN2014MN02082A (OSRAM) | ||
| MX2014013090A (es) | Derivados de pirrolotriazinona. | |
| MX336022B (es) | Activadores de pkm2 bicíclicos. | |
| TN2012000469A1 (en) | Use of novel pan-cdk inhibitors for treating tumors | |
| MX2021012705A (es) | Compuestos con actividad antitumoral contra las celulas cancerosas que portan mutaciones en el receptor del factor de crecimiento epidermico (egfr) resistentes al inhibidor de la tirosina quinasa. | |
| NZ611581A (en) | Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer | |
| PH12016500735A1 (en) | Substituted pyrimidine compounds and their use as syk inhibitors | |
| MX2011012524A (es) | Inhibidores de proteina cinasa c-met. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |